Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/268128
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

The α-Gliadins in Bread Wheat: Effect of Nitrogen Treatment on the Expression of the Major Celiac Disease Immunogenic Complex in Two RNAi Low-Gliadin Lines

AutorSánchez-León, Susana CSIC ORCID; Giménez, María J. CSIC ORCID; Barro Losada, Francisco CSIC ORCID
Palabras claveα-gliadins
Nitrogen
RNAi wheat
Celiac disease
Endosperm-specific promoters
Gluten
33-mer
Fecha de publicación29-abr-2021
EditorFrontiers Media
CitaciónFrontiers in Plant Science 12: 663653 (2021)
ResumenCeliac Disease (CD) is an autoimmune disorder that affects approximately 1% of the worldwide population. The α-gliadins of wheat contain the 33-mer peptide, the most active peptide in CD both in adults and pediatric patients. In this study, we have characterized the variants and expression profile of an α-gliadins amplicon, harboring the 33-mer peptide, in two low-gliadin RNAi wheat lines, under two different Nitrogen (N) treatments. We estimated that the amplicon expands 45 different α-gliadin variants with high variability due to length, randomly distributed SNPs, and the presence of encoded CD epitopes. Expression of this amplicon is reduced in both RNAi lines in comparison to the wild type. High N treatment significantly increases transcripts of the amplicon in the wild type, but not in the transgenic lines. Classification of α-gliadin variants, considering the number of epitopes, revealed that amplicon variants containing the full complement of 33-mer peptide were affected by N treatment, increasing their expression when N was increased. Line D793 provided higher and more stable silencing through different N fertilization regimes, expressing fewer CD epitopes than D783. Results of this study are important for better understanding of RNAi α-gliadin silencing in response to N treatments, and for undertaking new strategies by RNAi or CRISPR/Cas toward obtaining new varieties suitable for people suffering gluten intolerances.
Versión del editorhttp://dx.doi.org/10.3389/fpls.2021.663653
URIhttp://hdl.handle.net/10261/268128
DOI10.3389/fpls.2021.663653
Identificadoresdoi: 10.3389/fpls.2021.663653
e-issn: 1664-462X
Aparece en las colecciones: (IAS) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Major_Celiac_Disease.pdf2,61 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

2
checked on 18-may-2024

SCOPUSTM   
Citations

4
checked on 18-may-2024

WEB OF SCIENCETM
Citations

4
checked on 29-feb-2024

Page view(s)

42
checked on 19-may-2024

Download(s)

47
checked on 19-may-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons